TGFB1 and breast carcinoma: Consistent with this, the combination of RT and abemaciclib decreased the expression of TGF-β1/NF-κβ in MDA-MB-231 and MCF-7 cell lines, which could potentiate apoptosis and further hinder the proliferation of breast cancer cells.